1. August RX Product News.
- Subjects
- *
RESPIRATORY diseases , *ACUTE coronary syndrome , *JUVENILE idiopathic arthritis , *RESPIRATORY syncytial virus infections , *ISCHEMIC stroke , *SPONDYLOARTHROPATHIES , *TRANSIENT ischemic attack - Abstract
The approval was based on findings from the RENOIR trial (NCT05035212), showing that the vaccine demonstrated 66.7% efficacy against RSV-associated lower respiratory tract illness, which was defined as illness with 2 or more symptoms. From: Celltrion USA The FDA has approved adalimumab-aaty (Yuflyma), which is a high concentration, citrate-free biosimilar of adalimumab (Humira). FOR MORE INFORMATION: pfizer.com Respiratory Syncytial Virus Vaccine (Abrysvo) From: Pfizer Inc The FDA has approved the first respiratory syncytial virus (RSV) vaccine (Abrysvo) to prevent lower respiratory tract disease caused by RSV in individuals 60 years and older. [Extracted from the article]
- Published
- 2023